Published in Nat Rev Rheumatol on April 05, 2011
Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One (2013) 1.13
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis (2013) 1.06
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther (2012) 0.97
Endoplasmic reticulum stress in skeletal muscle homeostasis and disease. Curr Rheumatol Rep (2012) 0.94
Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol (2014) 0.90
Abacavir-reactive memory T cells are present in drug naïve individuals. PLoS One (2015) 0.90
Platelet-rich plasma promotes the proliferation of human muscle derived progenitor cells and maintains their stemness. PLoS One (2013) 0.88
New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr Rheumatol Rep (2014) 0.84
Autophagy, inflammation and innate immunity in inflammatory myopathies. PLoS One (2014) 0.82
Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther (2013) 0.81
Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents. Arthritis Res Ther (2016) 0.80
Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis. PLoS One (2012) 0.80
Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage. PLoS One (2014) 0.79
The use and abuse of diagnostic/classification criteria. Best Pract Res Clin Rheumatol (2015) 0.79
Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications. Clin Exp Immunol (2014) 0.79
Brief report: antisynthetase syndrome-associated myocarditis. J Card Fail (2014) 0.78
Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis. Arthritis Res Ther (2016) 0.77
Skeletal muscle interleukin 15 promotes CD8(+) T-cell function and autoimmune myositis. Skelet Muscle (2015) 0.76
The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies. Oncotarget (2015) 0.75
Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology (Oxford) (2014) 0.75
Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis. Sci Rep (2016) 0.75
Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. Sci Rep (2016) 0.75
Expression of tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 in patients with polymyositis and dermatomyositis. Arthritis Res Ther (2014) 0.75
Targeted immunotherapy trials for idiopathic inflammatory myopathies. J Neurol (2012) 0.75
[Inflammatory myopathies]. Z Rheumatol (2016) 0.75
The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis. Clin Rheumatol (2016) 0.75
Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review. Clin Rev Allergy Immunol (2017) 0.75
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord (2004) 2.85
Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum (2005) 1.89
Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann Rheum Dis (2012) 1.59
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest (2015) 1.51
Leukocytes, cytokines, growth factors and hormones in human skeletal muscle and blood after uphill or downhill running. J Physiol (2004) 1.49
Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol (2002) 1.35
A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum (2007) 1.31
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther (2009) 1.29
International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum (2007) 1.28
Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum (2003) 1.20
Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum (2008) 1.18
Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol (2013) 1.16
T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol (2009) 1.15
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther (2012) 1.11
Experiencing virtual patients in clinical learning: a phenomenological study. Adv Health Sci Educ Theory Pract (2011) 1.10
Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med (2007) 1.10
Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum (2007) 1.08
Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum (2008) 1.07
Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol (2005) 1.07
Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum (2004) 1.06
Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum (2007) 1.04
Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J (2009) 1.04
Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) (2010) 1.04
Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum (2006) 1.01
Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) (2012) 0.99
Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol (2010) 0.97
Expanded T cell receptor Vβ-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. Arthritis Rheum (2010) 0.97
Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. Muscle Nerve (2009) 0.96
Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol (2009) 0.94
Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol (2012) 0.94
Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum (2008) 0.94
Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum (2004) 0.94
Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis (2006) 0.93
A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med (2010) 0.93
Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford) (2013) 0.92
Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis. Arthritis Rheum (2009) 0.91
Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers. Rheumatology (Oxford) (2009) 0.91
Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med (2003) 0.90
Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther (2007) 0.90
Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. Arthritis Rheum (2007) 0.89
The role of TRAIL in mediating autophagy in myositis skeletal muscle: a potential nonimmune mechanism of muscle damage. Arthritis Rheum (2011) 0.87
Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2007) 0.87
TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis (2012) 0.87
Pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep (2006) 0.87
Cytokines in idiopathic inflammatory myopathies. Autoimmunity (2006) 0.87
Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol (2002) 0.86
Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology (Oxford) (2010) 0.84
Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum (2009) 0.84
New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr Rheumatol Rep (2014) 0.84
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum (2007) 0.84
Cardiovascular disease in patients with inflammatory rheumatic disease is associated with up-regulation of markers of inflammation in cardiac microvessels and cardiomyocytes. Arthritis Rheum (2010) 0.84
193rd ENMC International workshop Pathology diagnosis of idiopathic inflammatory myopathies 30 November - 2 December 2012, Naarden, The Netherlands. Neuromuscul Disord (2013) 0.84
Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis (2013) 0.83
Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun (2006) 0.83
Polymyositis and dermatomyositis: pathophysiology. Rheum Dis Clin North Am (2011) 0.83
Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol (2011) 0.82
Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis (2007) 0.82
Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther (2013) 0.81
Vascular involvement in the pathogenesis of idiopathic inflammatory myopathies. Autoimmunity (2009) 0.81
Development of the myositis activities profile--validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol (2002) 0.81
Interrater reliability and aspects of validity of the myositis damage index. Ann Rheum Dis (2011) 0.81
Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev (2009) 0.81
Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis (2012) 0.81
Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis. PLoS One (2012) 0.80
Proteomic profiling reveals autoimmune targets in sarcoidosis. Am J Respir Crit Care Med (2015) 0.80
Progressive multifocal leukoencephalopathy in a patient with polymyositis: case report and literature review. J Rheumatol (2012) 0.80
Idiopathic inflammatory myopathies - myositis. Best Pract Res Clin Rheumatol (2002) 0.78
Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group. J Rheumatol (2014) 0.78
Higher pain sensitivity and lower muscle strength in postmenonpausal women with early rheumatoid arthritis compared with age-matched healthy women--a pilot study. Disabil Rehabil (2013) 0.78
Elevated expression of prostaglandin E2 synthetic pathway in skeletal muscle of prior polio patients. J Rehabil Med (2014) 0.78
Clinical symptoms in patients with myositis-an acquired metabolic myopathy? Curr Opin Rheumatol (2003) 0.77
Activated LTB4 pathway in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis (2012) 0.77
The role of exercise in the rehabilitation of idiopathic inflammatory myopathies. Curr Opin Rheumatol (2005) 0.76
Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Res Ther (2014) 0.76
New possibilities to achieve increased understanding of disease mechanisms in idiopathic inflammatory myopathies. Curr Opin Rheumatol (2002) 0.76
CBA/J mice infected with Trypanosoma cruzi: an experimental model for inflammatory myopathies. Muscle Nerve (2003) 0.76
Inflammatory muscle disease: clinical presentation and assessment of patients. Curr Rheumatol Rep (2007) 0.76
Hand exercise intervention in patients with polymyositis and dermatomyositis: a pilot study. Musculoskeletal Care (2014) 0.75
Expression of High Mobility Group Protein B1 in Cardiac Tissue of Elderly Patients with Coronary Artery Disease with or without Inflammatory Rheumatic Disease. Gerontology (2017) 0.75
Treatment-resistant inflammatory myopathy. Best Pract Res Clin Rheumatol (2010) 0.75
Cardiomyopathy in murine models of systemic sclerosis. Arthritis Rheumatol (2015) 0.75
Recent clinical trials in idiopathic inflammatory myopathies. Curr Opin Rheumatol (2017) 0.75
Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis. Clin Exp Rheumatol (2014) 0.75
MICA4/HLA-DRB1*04/TNF1 haplotype is associated with mixed connective tissue disease in Swedish patients. Hum Immunol (2003) 0.75
[Temporal arteritis]. Lakartidningen (2005) 0.75